Robyn Karnauskas
Stock Analyst at Truist Securities
(1.92)
# 3,177
Out of 5,124 analysts
177
Total ratings
43.79%
Success rate
-0.1%
Average return
Main Sectors:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $1,038 → $1,182 | $1,058.18 | +11.70% | 6 | Nov 19, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $3.16 | +216.46% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $384.32 | -22.46% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $61.99 | +4.86% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $121.93 | -9.78% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $152.50 | -45.57% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $223.43 | -6.01% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.22 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $201.18 | +69.00% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $1.03 | +2,424.27% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $2.14 | +227.10% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $785.51 | +44.49% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.70 | +488.24% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $2.70 | +233.95% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $25.82 | -10.92% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $27.05 | +77.45% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $21.03 | +137.76% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $477.92 | +6.29% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $27.22 | +32.26% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $74.68 | -66.52% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.50 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $58.13 | +140.84% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $2.22 | +1,351,251.35% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.14 | +514.04% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $25.65 | +114.42% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $7.77 | +4,018.40% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $23.04 | -34.90% | 5 | Aug 9, 2022 |
Eli Lilly and Company
Nov 19, 2025
Maintains: Buy
Price Target: $1,038 → $1,182
Current: $1,058.18
Upside: +11.70%
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $3.16
Upside: +216.46%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $384.32
Upside: -22.46%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $61.99
Upside: +4.86%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $121.93
Upside: -9.78%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $152.50
Upside: -45.57%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $223.43
Upside: -6.01%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.22
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $201.18
Upside: +69.00%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $1.03
Upside: +2,424.27%
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $2.14
Upside: +227.10%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $785.51
Upside: +44.49%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.70
Upside: +488.24%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $2.70
Upside: +233.95%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $25.82
Upside: -10.92%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $27.05
Upside: +77.45%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $21.03
Upside: +137.76%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $477.92
Upside: +6.29%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $27.22
Upside: +32.26%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $74.68
Upside: -66.52%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.50
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $58.13
Upside: +140.84%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $2.22
Upside: +1,351,251.35%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.14
Upside: +514.04%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $25.65
Upside: +114.42%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $7.77
Upside: +4,018.40%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $23.04
Upside: -34.90%